HK1147938A1 - Therapeutic isoxazole compounds - Google Patents
Therapeutic isoxazole compoundsInfo
- Publication number
- HK1147938A1 HK1147938A1 HK11102049.4A HK11102049A HK1147938A1 HK 1147938 A1 HK1147938 A1 HK 1147938A1 HK 11102049 A HK11102049 A HK 11102049A HK 1147938 A1 HK1147938 A1 HK 1147938A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- isoxazole compounds
- therapeutic
- therapeutic isoxazole
- compounds
- isoxazole
- Prior art date
Links
- 150000002545 isoxazoles Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96820507P | 2007-08-27 | 2007-08-27 | |
PCT/US2008/074353 WO2009029632A1 (en) | 2007-08-27 | 2008-08-26 | Therapeutic isoxazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1147938A1 true HK1147938A1 (en) | 2011-08-26 |
Family
ID=40387754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11102049.4A HK1147938A1 (en) | 2007-08-27 | 2011-03-01 | Therapeutic isoxazole compounds |
Country Status (12)
Country | Link |
---|---|
US (5) | US8222243B2 (bg) |
EP (2) | EP2182809B1 (bg) |
JP (3) | JP5718053B2 (bg) |
KR (2) | KR101567454B1 (bg) |
CN (2) | CN104072489B (bg) |
AU (2) | AU2008293542B9 (bg) |
CA (2) | CA2974477C (bg) |
ES (2) | ES2748599T3 (bg) |
HK (1) | HK1147938A1 (bg) |
IL (3) | IL203910A (bg) |
MX (1) | MX2010002258A (bg) |
WO (1) | WO2009029632A1 (bg) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2545178T3 (es) | 2005-07-26 | 2015-09-09 | Bial-Portela & Ca, S.A. | Derivados de nitrocatecol como inhibidores de la COMT |
EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
SI2481410T1 (sl) | 2007-01-31 | 2017-01-31 | Bial - Portela & Ca., S.A. | Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom |
CA2974477C (en) | 2007-08-27 | 2019-12-31 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
RU2010139315A (ru) | 2008-03-17 | 2012-04-27 | Биал - Портела Энд Ка., С.А. (Pt) | Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола |
DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
KR102329271B1 (ko) | 2009-04-01 | 2021-11-22 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
WO2011076725A1 (en) * | 2009-12-21 | 2011-06-30 | Bayer Cropscience Ag | Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
CN102229606B (zh) * | 2011-06-03 | 2014-07-02 | 浙江工业大学 | 含异噁唑杂环的2-甲基苯并呋喃类衍生物及制备与应用 |
CN102229603B (zh) * | 2011-06-03 | 2014-07-02 | 浙江工业大学 | 含三唑杂环的2-甲基苯并呋喃类化合物及其制备与应用 |
BR112014000371A2 (pt) | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
WO2013066839A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
JP5966014B2 (ja) * | 2011-11-28 | 2016-08-10 | ノバルティス アーゲー | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 |
CA3088684C (en) | 2011-12-13 | 2021-10-26 | Bial - Portela & C.A., S.A. | Compound 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol in microparticulate form and its use in the treatment of parkinson's disease |
CN105143190B (zh) | 2013-03-14 | 2017-08-18 | 达特神经科学(开曼)有限公司 | 作为mao抑制剂的被取代的萘啶和喹啉化合物 |
SG11201504709PA (en) | 2013-03-14 | 2015-07-30 | Dart Neuroscience Llc | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
CN104016939B (zh) * | 2014-05-28 | 2016-06-15 | 浙江工业大学 | 一种2-亚乙基-3-乙酰基-1,3,4-噁二唑类化合物及其制备与应用 |
CN104016938B (zh) * | 2014-05-28 | 2016-08-17 | 浙江工业大学 | 一种含苯硒基的噁二唑类化合物及其制备与应用 |
WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
WO2016179428A2 (en) | 2015-05-05 | 2016-11-10 | Dart Neuroscience, Llc | Cognitive test execution and control |
UY37623A (es) * | 2017-03-03 | 2018-09-28 | Syngenta Participations Ag | Derivados de oxadiazol tiofeno fungicidas |
WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
WO2018202487A1 (en) | 2017-05-04 | 2018-11-08 | Basf Se | Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for combating phytopathogenic fungi |
EP3728243A1 (en) * | 2017-12-22 | 2020-10-28 | Bayer Aktiengesellschaft | Hydroxyisoxazolines and derivatives thereof |
US10902558B2 (en) * | 2018-05-18 | 2021-01-26 | Gopro, Inc. | Multiscale denoising of raw images with noise estimation |
US10853215B2 (en) * | 2018-09-10 | 2020-12-01 | Microsoft Technology Licensing, Llc | Intelligent configuration management of user devices |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB935523A (en) * | 1961-06-17 | 1963-08-28 | Acraf | New sulphamido-oxadiazoles |
GB1051322A (bg) * | 1967-08-09 | |||
US3995048A (en) * | 1975-10-20 | 1976-11-30 | Sandoz, Inc. | Isoxazolyl benzamides useful as tranquilizers and sleep-inducers |
AU576868B2 (en) | 1984-06-11 | 1988-09-08 | E.I. Du Pont De Nemours And Company | Thiophene and pyridine sulfonamides |
JPS6183181A (ja) * | 1984-06-11 | 1986-04-26 | イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− | 除草剤性チオフエンスルホンアミド類およびピリジンスルホンアミド類 |
DE3602016A1 (de) | 1985-12-05 | 1987-06-11 | Bayer Ag | Pyri(mi)dyl-oxy- und thio-benzoesaeure-derivate |
DD265317A5 (de) * | 1985-12-05 | 1989-03-01 | Bayer Ag,De | Herbizide und pflanzenwuchsregulierende mittel |
US5204482A (en) | 1988-07-28 | 1993-04-20 | Hoffman-Laroche Inc. | Compounds for treating and preventing cognitive diseases and depression and methods of making same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US5047554A (en) * | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
DE3929233A1 (de) * | 1989-09-02 | 1991-03-07 | Bayer Ag | 5-heterocyclyl-pyridin-3-carbon-benzylamide und -anilide |
DE4126937A1 (de) * | 1991-08-10 | 1993-02-11 | Basf Ag | Salicyl(thio)etherderivate, verfahren und zwischenprodukte zu ihrer herstellung |
GB2265371A (en) * | 1992-03-06 | 1993-09-29 | Shell Int Research | Isoxazole compounds |
US5246914A (en) * | 1992-08-07 | 1993-09-21 | Basf Aktiengesellschaft | Salicyloyl (thio)ether derivatives, their preparation and intermediates for their preparation |
AU699593B2 (en) * | 1995-02-13 | 1998-12-10 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
WO1997046530A1 (en) * | 1996-06-06 | 1997-12-11 | E.I. Du Pont De Nemours And Company | Herbicidal pyridinyl and pyrazolylphenyl ketones |
WO1998037068A1 (en) * | 1997-02-21 | 1998-08-27 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
JP2001520655A (ja) | 1997-04-16 | 2001-10-30 | アボツト・ラボラトリーズ | 5,7−ジ置換4−アミノピリド[2,3−d]ピリミジン化合物およびアデノシンキナーゼ阻害剤としてのその用途 |
JPH11139975A (ja) * | 1997-08-26 | 1999-05-25 | Sankyo Co Ltd | A型モノアミンオキシダーゼ阻害薬 |
DE19743435A1 (de) * | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
JP4385414B2 (ja) | 1997-10-13 | 2009-12-16 | アステラス製薬株式会社 | アミド若しくはアミン誘導体 |
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
DE19904389A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
PL351374A1 (en) * | 1999-04-19 | 2003-04-07 | Shionogi & Co | Sulfonamide derivatives having oxadiazole rings |
PE20010628A1 (es) | 1999-10-01 | 2001-06-18 | Takeda Chemical Industries Ltd | Compuestos de amina ciclica, su produccion y su uso |
US7291641B2 (en) | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
AU4398801A (en) | 2000-03-22 | 2001-10-03 | Banyu Pharmaceutical Co., Ltd. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
RU2275371C2 (ru) | 2000-04-21 | 2006-04-27 | Шионоги Энд Ко., Лтд. | Производные оксадиазола, обладающие противоопухолевым действием, лекарственное средство, их содержащее, и способ лечения |
JP2001316378A (ja) * | 2000-04-28 | 2001-11-13 | Takeda Chem Ind Ltd | ベンズアミド誘導体およびその用途 |
US6579880B2 (en) * | 2000-06-06 | 2003-06-17 | Ortho-Mcneil Pharmaceutical, Inc. | Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8 |
WO2002016355A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
HUP0302991A3 (en) * | 2000-09-15 | 2009-10-28 | Vertex Pharma | Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds |
IL157491A0 (en) | 2001-02-21 | 2004-03-28 | Nps Pharmeceuticals Inc | Heteropolycyclic compounds and pharmaceutical compositions containing the same |
EP1405636A4 (en) | 2001-06-26 | 2009-04-15 | Takeda Pharmaceutical | REGULATOR OF RECTINTOR FUNCTION RELATING TO RETINOIDS |
US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
CN1671386A (zh) | 2001-07-05 | 2005-09-21 | H·隆德贝克有限公司 | 作为mch选择性拮抗剂的取代苯胺基哌啶 |
WO2003018585A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
US6660736B2 (en) * | 2002-03-27 | 2003-12-09 | Hoffmann-La Roche Inc. | Phthalimido derivatives and a process for their preparation |
TW200400035A (en) * | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
US7329401B2 (en) * | 2002-04-15 | 2008-02-12 | The Regents Of The University Of California | Cyclooxygenase-2 selective agents useful as imaging probes and related methods |
AU2003222648A1 (en) | 2002-05-13 | 2003-12-02 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
RU2005105696A (ru) * | 2002-08-02 | 2005-11-10 | Арджента Дискавери Лимитед (Gb) | Замещенные тиенилгидроксамовые кислоты в качестве ингибиторов гистондеацетилазы |
PT1540335E (pt) | 2002-08-19 | 2010-06-23 | Helicon Therapeutics Inc | Métodos de identificação de estimuladores cognitivos |
AR043048A1 (es) * | 2002-08-30 | 2005-07-13 | Syngenta Participations Ag | Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas |
SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
PT1611112E (pt) | 2003-02-11 | 2012-11-02 | Cancer Rec Tech Ltd | Compostos de isoxazole como inibidores de proteínas de choque térmico |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
WO2004076418A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
WO2004085401A1 (en) | 2003-03-28 | 2004-10-07 | Pfizer Products Inc. | 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
DE10315571A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Pyrazolverbindungen |
WO2004089367A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
WO2005004021A1 (ja) | 2003-07-07 | 2005-01-13 | Fujitsu Limited | サービス提供装置、方法及びプログラム |
US7199149B2 (en) | 2003-10-01 | 2007-04-03 | Bristol Myers Squibb Company | Monocyclic and bicyclic lactams as factor Xa inhibitors |
GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
CN1894206A (zh) * | 2003-12-15 | 2007-01-10 | 日本烟草产业株式会社 | N-取代的n-磺酰氨基环丙烷化合物和其药学应用 |
EP2305671A1 (en) | 2004-01-05 | 2011-04-06 | AstraZeneca AB | Thiophene and thiazole derivatives as CHK1 inhibitors |
DK1731512T3 (en) * | 2004-03-05 | 2015-01-05 | Nissan Chemical Ind Ltd | Isoxazoline-substituted benzamide AND INSTRUMENTS FOR COMBATING HARMFUL ORGANISMS |
TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
CN101031293A (zh) * | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US20080138282A1 (en) * | 2004-06-03 | 2008-06-12 | The Trustees Of Columbia University In The City Of New York | Radiolabeled Arylsulfonyl Compounds and Uses Thereof |
WO2006008133A2 (en) * | 2004-07-20 | 2006-01-26 | Siena Biotech S.P.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
GB0418267D0 (en) * | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
US7338967B2 (en) | 2004-09-10 | 2008-03-04 | Syngenta Limited | Substituted isoxazoles as fungicides |
WO2006046916A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
US7419962B2 (en) * | 2004-12-07 | 2008-09-02 | Enanta Pharmaceuticals, Inc. | 3,6-bicyclolides |
US8338614B2 (en) * | 2005-01-19 | 2012-12-25 | Merck, Sharp & Dohme Corp. | Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease |
GB0504103D0 (en) * | 2005-02-28 | 2005-04-06 | Syngenta Ltd | Novel method |
JP2006316054A (ja) * | 2005-04-15 | 2006-11-24 | Tanabe Seiyaku Co Ltd | 高コンダクタンス型カルシウム感受性kチャネル開口薬 |
WO2006134481A1 (en) * | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
NZ564916A (en) | 2005-06-27 | 2011-03-31 | Exelixis Inc | Imidazole based LXR modulators |
JP5114395B2 (ja) * | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Gpcrアゴニスト |
US20080234349A1 (en) | 2005-09-07 | 2008-09-25 | Jack Lin | PPAR active compounds |
PE20110118A1 (es) * | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
US7947707B2 (en) * | 2005-10-07 | 2011-05-24 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
GB0603041D0 (en) * | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
BRPI0708353A8 (pt) * | 2006-02-28 | 2017-09-19 | Dart Neuroscience Cayman Ltd | Compostos terapêuticos |
US20070259879A1 (en) * | 2006-03-06 | 2007-11-08 | Trimeris, Inc. | Piperazine and piperidine biaryl derivatives |
CN101541331A (zh) | 2006-08-24 | 2009-09-23 | 沃克哈特研究中心 | 具有抗微生物活性的新颖大环内酯和酮内酯 |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
CN101646656B (zh) | 2007-03-30 | 2013-08-14 | 塞诺菲-安万特股份有限公司 | 作为pgds抑制剂的嘧啶酰肼化合物 |
CA2974477C (en) | 2007-08-27 | 2019-12-31 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
-
2008
- 2008-08-26 CA CA2974477A patent/CA2974477C/en not_active Expired - Fee Related
- 2008-08-26 CA CA2696609A patent/CA2696609C/en not_active Expired - Fee Related
- 2008-08-26 WO PCT/US2008/074353 patent/WO2009029632A1/en active Application Filing
- 2008-08-26 KR KR1020107006239A patent/KR101567454B1/ko active IP Right Grant
- 2008-08-26 ES ES17204892T patent/ES2748599T3/es active Active
- 2008-08-26 EP EP08828742.0A patent/EP2182809B1/en not_active Not-in-force
- 2008-08-26 EP EP17204892.8A patent/EP3311813B1/en not_active Not-in-force
- 2008-08-26 KR KR1020157012712A patent/KR101669432B1/ko active IP Right Grant
- 2008-08-26 JP JP2010523095A patent/JP5718053B2/ja not_active Expired - Fee Related
- 2008-08-26 ES ES08828742.0T patent/ES2663517T3/es active Active
- 2008-08-26 CN CN201410184138.1A patent/CN104072489B/zh not_active Expired - Fee Related
- 2008-08-26 AU AU2008293542A patent/AU2008293542B9/en not_active Ceased
- 2008-08-26 CN CN200880110343.6A patent/CN101820764B/zh not_active Expired - Fee Related
- 2008-08-26 MX MX2010002258A patent/MX2010002258A/es active IP Right Grant
- 2008-08-26 US US12/198,686 patent/US8222243B2/en active Active
-
2010
- 2010-02-11 IL IL203910A patent/IL203910A/en active IP Right Review Request
-
2011
- 2011-03-01 HK HK11102049.4A patent/HK1147938A1/xx not_active IP Right Cessation
-
2012
- 2012-04-16 US US13/448,052 patent/US8921399B2/en not_active Expired - Fee Related
- 2012-07-05 US US13/542,358 patent/US9029397B2/en active Active
-
2013
- 2013-06-03 IL IL226702A patent/IL226702A/en active IP Right Grant
-
2014
- 2014-05-01 IL IL232406A patent/IL232406A/en active IP Right Grant
- 2014-05-26 AU AU2014202864A patent/AU2014202864B2/en not_active Ceased
-
2015
- 2015-03-13 JP JP2015050436A patent/JP2015110666A/ja not_active Withdrawn
- 2015-05-11 US US14/709,206 patent/US9650349B2/en active Active
-
2016
- 2016-07-13 JP JP2016138293A patent/JP6250746B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-04 US US15/479,086 patent/US10053467B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL232406A (en) | Therapeutic isoxazole compounds | |
EP2211620A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0610680D0 (en) | Therapeutic compounds | |
IL193678A0 (en) | Therapeutic compounds | |
GB0603041D0 (en) | Therapeutic compounds | |
HK1203925A1 (en) | Therapeutic compounds | |
GB0813087D0 (en) | Therapeutic compounds | |
GB0716532D0 (en) | Therapeutic compounds | |
GB0606663D0 (en) | Therapeutic compounds | |
EP2164324A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0615809D0 (en) | Therapeutic compounds | |
GB0612971D0 (en) | Therapeutic compounds | |
EP2185568A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0625349D0 (en) | Therapeutic compounds | |
EP2079704A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0625345D0 (en) | Therapeutic compounds | |
GB0605573D0 (en) | Therapeutic Compounds | |
GB0603455D0 (en) | Therapeutic compounds | |
GB0702862D0 (en) | Therapeutic compounds | |
GB0608269D0 (en) | Therapeutic compounds | |
GB0708188D0 (en) | Therapeutic compounds | |
GB2439923B (en) | Therapeutic compounds | |
GB0717573D0 (en) | Therapeutic compounds | |
GB0707359D0 (en) | Therapeutic compounds | |
GB0724635D0 (en) | Therapeutic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210826 |